// App-Quantinova.ai

POS0683 (2021) : NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS

Researchers

Presenter

  • D. Isenberg

Principal Investigators

  • I. N. Bruce

  • R. Furie

  • E. F. Morand

  • Y. Tanaka

  • S. Manzi

  • K. Kalunian

  • R. Tummala

Medical Centers

  • University College London, Centre for Rheumatology and Bloomsbury Rheumatology Unit, London, United Kingdom

  • King's College Hospital, Department of Rheumatology, London, London, United Kingdom

  • The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom

  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dermatology, Hempstead, United States of America

  • Monash University, Centre for Inflammatory Disease Monash Health, Melbourne, Australia

  • University of Occupational and Environmental Health, Japan, The second department on internal medicine, Kitakyusyu, Japan

  • Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Rheumatology, Pittsburgh, United States of America

  • University of California San Diego”, Division of Rheumatology, Allergy and Immunology, La Jolla, United States of America

  • AstraZeneca Pharmaceuticals, Cambridge, United Kingdom

Locations

  • United Kingdom

  • United States

  • Australia

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • MDX1333

  • MUSE

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II

Study Id's

  • NCT01438489

  • NCT02446912

  • NCT02446899

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved